We are live on ! Find out more
CORT icon

Corcept Therapeutics

63.62 USD
-1.36
2.09%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
63.62
0.00
0%
1 day
-2.09%
5 days
-12.02%
1 month
-45.37%
3 months
-47.44%
6 months
7.72%
Year to date
66.54%
1 year
-15.23%
5 years
172.58%
10 years
580.43%
 

About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Employees: 730

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 47.8%
Neutral 47.8%
Negative 4.3%
Positive
Seeking Alpha
13 hours ago
Corcept Therapeutics: Two Franchises, But One Broader Cortisol Opportunity
I rate Corcept Therapeutics Incorporated Buy with an $82 target; growth opportunities appear underappreciated, and my base case does not require Cushing's approval. CORT Q3 revenue rose 64% to $340.5 million as Korlym grew despite generic competition and Lifyorli gained traction. The December 17 FDA decision and Teva litigation could drive significant volatility; I would size positions cautiously.
Corcept Therapeutics: Two Franchises, But One Broader Cortisol Opportunity
Neutral
Business Wire
4 days ago
ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced publication of a peer-reviewed case report in ESMO Rare Cancers, regarding an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulva.
ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
Positive
Zacks Investment Research
16 days ago
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues
Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues
Neutral
Seeking Alpha
17 days ago
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
Positive
MarketBeat
17 days ago
Corcept Therapeutics Q3 Earnings Call Highlights
Corcept Therapeutics NASDAQ: CORT reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer treatment Lifyorli lifted results.
Corcept Therapeutics Q3 Earnings Call Highlights
Positive
Zacks Investment Research
17 days ago
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.16 per share a year ago.
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Neutral
Business Wire
17 days ago
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the third quarter. Financial Results “Awareness of the importance of diagnosing and treating patients with Cushing's syndrome is steadily increasing and is driving the.
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
Neutral
Business Wire
24 days ago
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique acces.
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Neutral
Business Wire
25 days ago
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from Part A of the company's Phase 2 BELLA trial, which evaluated Lifyorli in combination with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant.
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
Neutral
Business Wire
1 month ago
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published their consensus report on the Management of Type 2 Diabetes, 2026.
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
Price charts implemented using Lightweight Charts™